Biotech Stock Screener
Screen biotech and pharmaceutical stocks by FDA catalysts, PDUFA dates, and clinical trial readouts. Find high-impact investment opportunities in biotechnology.
Biotech Screening Strategies
High-Impact Imminent
Stocks with high-impact catalysts within 90 days
Strategy: Binary event trading with defined risk position sizing
Phase 3 Pipeline
Companies with Phase 3 trials - highest probability of FDA approval
Strategy: Focus on late-stage assets with strong Phase 2 data
Catalyst Density
Companies with multiple catalysts - more chances to win
Strategy: Diversified pipeline plays with multiple shots on goal
Near-Term Movers
Stocks with events in the next 30 days
Strategy: Short-term catalyst plays with tight risk management
Understanding Screener Metrics
Catalyst Count
Total number of upcoming FDA events, trial readouts, and milestones for the company
Why it matters: More catalysts = more chances for positive surprises
Imminent Events
Catalysts expected within the next 90 days
Why it matters: Near-term events drive immediate stock movement
Phase 3 Trials
Late-stage trials with highest FDA approval probability (25-30%)
Why it matters: Phase 3 success often leads to FDA approval within 12-18 months
Days Until
Time until the nearest catalyst event
Why it matters: Stocks often run up 2-4 weeks before major catalysts
Impact Level
Expected stock price impact based on catalyst type and phase
Why it matters: High-impact events can move stocks 50-200%
Biotech Investment Risk Warning
Biotech stocks are among the most volatile investments. Clinical trials have high failure rates (only 10% of drugs in Phase 1 reach FDA approval), and binary events can cause 50-70% losses overnight. This screener is for educational purposes only and does not constitute investment advice.
- • Never invest more than you can afford to lose in any single biotech position
- • Diversify across multiple stocks, therapeutic areas, and development stages
- • Consider using options for defined-risk binary event exposure
- • Conduct thorough due diligence beyond this screener data
Frequently Asked Questions
How do I use the biotech stock screener?▼
The biotech screener helps you find pharmaceutical and biotechnology stocks with upcoming FDA catalysts. Use filters to narrow by: imminent events (within 90 days), high-impact catalysts, Phase 3 trials, or minimum catalyst count. Click on any stock row to see its detailed catalyst timeline. Sort by different columns to find stocks matching your investment strategy.
What catalysts does this screener track?▼
The screener tracks FDA approval decisions (PDUFA dates), clinical trial readouts (Phase 1/2/3), interim data analyses, regulatory designations (Breakthrough, Fast Track), and other pipeline milestones. Data is sourced from ClinicalTrials.gov, FDA filings, and company announcements. Each catalyst is rated by importance (HIGH/MEDIUM/LOW) based on its potential stock price impact.
Should I invest in stocks with imminent catalysts?▼
Imminent catalysts (within 90 days) offer high reward potential but also high risk. Positive Phase 3 results can double a stock, while failures can cause 50-70% crashes. Consider: 1) Position size appropriately (max 5% per binary bet), 2) Use options for defined risk, 3) Diversify across multiple biotech names, 4) Research the trial design and competitive landscape before investing.
What makes a biotech catalyst "high impact"?▼
High-impact catalysts typically include: Phase 3 pivotal trial readouts, FDA approval decisions (PDUFA dates), major label expansions, and Breakthrough Therapy designations. Impact is determined by: trial phase (Phase 3 > Phase 2 > Phase 1), market size of the indication, competitive landscape, and historical stock volatility around similar events.
How do I reduce risk when trading biotech catalysts?▼
Risk management strategies include: 1) Limit position size to 3-5% of portfolio per binary event, 2) Use options instead of stock for defined maximum loss, 3) Spread risk across 5-10 biotech names, 4) Focus on companies with multiple catalysts (more shots on goal), 5) Consider selling partial positions before binary events to lock in gains, 6) Set stop losses at predetermined levels.
What is the best biotech screening strategy?▼
The optimal strategy depends on your risk tolerance. Conservative: Screen for Phase 3 stocks with multiple catalysts and proven management. Moderate: Filter for high-impact events 60-90 days out, buying the anticipation. Aggressive: Trade imminent catalysts (30 days or less) with tight position sizing. Most successful biotech investors combine strategies and diversify across multiple names and therapeutic areas.
How often is the catalyst data updated?▼
Catalyst data is refreshed from ClinicalTrials.gov and FDA sources regularly. Trial completion dates may shift based on enrollment and protocol amendments. Always verify critical dates with company investor relations or SEC filings before making investment decisions. Setting calendar alerts for key dates helps you stay informed.
What does "Phase 3" mean for biotech stocks?▼
Phase 3 is the final stage of clinical trials before FDA submission. It involves 300-3,000+ patients and tests whether the drug is effective and safe for the intended population. Phase 3 trials have a 25-30% success rate - higher than earlier phases. Positive Phase 3 results often lead to FDA approval within 12-18 months and can cause 50-200% stock appreciation.
Track More Biotech Catalysts
View the full FDA calendar and get detailed stock analysis for any biotech company